OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.67
−1.37%Next report
Analyst consensus
- Next report date
- Dec 18, 2026
- EPS estimate
- -$0.06
- Revenue estimate
- $2.7M
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.08
- Revenue actual
- —
- Revenue estimate
- $966.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -33.3%
- Revenue beats (12Q)
- 0
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $5.37
- PT range
- $1.60 – $11
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.08 | -$0.14 | Miss -75.00% | — |
| May 15, 2026 | -$0.12 | -$0.16 | Miss -33.33% | $128.0K |
| Feb 17, 2026 | -$0.17 | -$0.22 | Miss -29.41% | -$1.2M |
| Dec 19, 2025 | -$0.23 | -$0.22 | Beat 4.35% | -$91.8K |
| Aug 14, 2025 | -$0.42 | -$0.44 | Miss -4.76% | $1.5M |
| May 15, 2025 | -$0.55 | -$0.40 | Beat 27.27% | — |
| Feb 14, 2025 | -$0.85 | -$0.89 | Miss -4.71% | — |
| Dec 27, 2024 | -$0.83 | -$0.77 | Beat 7.23% | — |
| Aug 14, 2024 | -$1.06 | -$0.83 | Beat 21.70% | — |
| May 15, 2024 | -$0.88 | -$1.55 | Miss -76.14% | — |
| Feb 14, 2024 | -$1.00 | -$0.80 | Beat 20.00% | — |
| Dec 22, 2023 | -$1.00 | -$1.00 | In line | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 18, 2026